Latest Biotech News

Illumina reported modest top‑line growth in Q4 and flat full‑year 2025 revenue while flagging an acceleration in clinical sequencing consumables. CEO Jacob Thaysen said clinical,...

Adaptive Biotechnologies projected robust growth for its minimal residual disease (MRD) business in 2026, guiding MRD revenue to $255–$265 million and forecasting a roughly 30% increase in...

Formation Bio described an AI‑native development model that combines in‑licensed assets and a centralized data‑driven development engine to speed clinical execution and cut costs. CTO Dan Neil...

Researchers published a Nature Communications study showing that combining bacteriophage therapy with standard antibiotics cleared refractory, drug‑resistant Klebsiella pneumoniae peritonitis in...

Researchers reported a stabilized MERS‑CoV spike displayed on a ferritin nanoparticle scaffold that generated potent immunogenicity in preclinical testing, positioning nanoparticle display as a...

Bayer disclosed Phase 3 results showing its Factor XIa inhibitor asundexian reduced the risk of secondary ischemic stroke by 26% without increasing major bleeding, according to conference data and...

Telehealth provider Hims & Hers began offering a compounded oral version of Novo Nordisk’s Wegovy this week, triggering immediate backlash from regulators and industry peers. Novo Nordisk has...

The Department of Health and Human Services moved to drop its contested 340B rebate pilot after facing legal challenges from hospitals and providers. HHS’ withdrawal follows court action that had...

Biotech fundraising on public markets showed renewed momentum this week as Eikon Therapeutics priced a $381 million IPO and peers Agomab and SpyGlass raised a combined $350 million. The flurry of...

Bayer released Phase 3 data showing its factor XIa inhibitor asundexian reduced the risk of secondary ischemic stroke by 26% without increasing bleeding, a result the company described as a...

uniQure halted mid- and high-dose cohorts in its Fabry AAV gene‑therapy study following reports of grade 3 liver enzyme elevations in two patients. The company disclosed dose-limiting toxicities...

Illumina reported a 5% gain in fourth‑quarter revenue and flat full‑year 2025 revenue, driven by stronger clinical sequencing consumables sales even as China revenues lagged. Management...

Formation Bio outlined its AI‑native hub‑and‑spoke model to accelerate clinical development, telling investors and partners the platform can cut cost and time across trial design, execution and...

Roivant spinout Priovant and its backers—including Pfizer—reported Phase 2 results showing brepocitinib achieved statistically and clinically meaningful improvements in cutaneous sarcoidosis,...

A Spanish research consortium unveiled a CRISPR‑based gene‑editing approach that selectively targets tumors bearing oncogene amplifications, exploiting those amplifications as vulnerabilities to...

Adaptive Biotechnologies raised its 2026 guidance as demand for its ClonoSeq minimal residual disease (MRD) assay continues to expand. Management forecasted 20%+ MRD revenue growth and said...

Telehealth firm Hims & Hers began selling a compounded version of Novo Nordisk’s newly approved Wegovy pill, prompting immediate regulatory and industry backlash. The move has drawn public...

The White House launched TrumpRx, a direct-to-consumer drug pricing platform, and several major manufacturers immediately joined with discount programs. Officials positioned the platform as a way...

Biotech deal activity accelerated this week with several drug developers completing high‑profile public offerings to fund clinical programs. Eikon Therapeutics priced an upsized IPO that will...

UniQure has paused mid and high dose cohorts in its AAV gene therapy trial for Fabry disease after two patients experienced grade 3 liver enzyme elevations. The company reported the dosing holds...